Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone ER in Geriatric Schizophrenia
NCT00085748Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of paliperidone in schizophrenia (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Safety and Tolerability. Started Aug 2004; status: completed.
02
Drugs
paliperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00085748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085748.